|
Re: Short interest keeps going higher....
|
4
|
Resverlogix Corp.
|
Oct 05, 2016 09:59PM
|
|
Re: Interesting paper on BET inhibitors and Memory
|
4
|
Resverlogix Corp.
|
Jan 27, 2019 09:39PM
|
|
Re: At least RVX has a shorter trial timeline than ESPR
|
4
|
Resverlogix Corp.
|
May 05, 2016 05:42PM
|
|
Re: Statistical Considerations
|
4
|
Resverlogix Corp.
|
Mar 07, 2018 11:17PM
|
|
Re: Zenith related comments from GAC's Bloom Burton Experience
|
4
|
Zenith Epigenetics
|
May 07, 2018 01:31PM
|
|
Re: Late Breaker program?
|
4
|
Resverlogix Corp.
|
Mar 23, 2020 12:04AM
|
|
Re: BETonMACE paper just published
|
4
|
Resverlogix Corp.
|
Mar 28, 2020 11:55AM
|
|
Re: Rheumatoid Arthritis
|
4
|
Resverlogix Corp.
|
Feb 04, 2017 12:14AM
|
|
2019 Potential Events
|
4
|
Resverlogix Corp.
|
Nov 27, 2018 12:02PM
|
|
Re: NYAS Symposium on Apr 28
|
4
|
Resverlogix Corp.
|
Apr 21, 2016 04:03PM
|
|
Re: The waiting game.....
|
4
|
Resverlogix Corp.
|
Jan 17, 2019 10:31AM
|
|
Re: Share price - some thoughts
|
4
|
Resverlogix Corp.
|
Aug 01, 2017 11:19AM
|
|
Re: About that stroke failure
|
4
|
Resverlogix Corp.
|
Dec 13, 2019 01:52PM
|
|
Re: Talking about an SSRA like its a slam dunk????
|
4
|
Resverlogix Corp.
|
Jun 25, 2018 02:38PM
|
|
Re: Novartis Phase III study shows Canakinumab reduces MACE events
|
4
|
Resverlogix Corp.
|
Jun 22, 2017 01:06PM
|
|
Resverlogix in the next 2.5 weeks (plus bonus October event)
|
4
|
Resverlogix Corp.
|
Aug 28, 2016 10:38PM
|
|
Re: After the dust settles in 3 weeks
|
4
|
Resverlogix Corp.
|
Nov 09, 2015 10:46AM
|
|
Reports of exempt distribution on SEDAR
|
4
|
Resverlogix Corp.
|
Mar 28, 2018 11:09PM
|
|
Re: RVX, protein, inflammation and MS
|
4
|
Resverlogix Corp.
|
Mar 28, 2017 11:05AM
|
|
Re: Roll call,...
|
4
|
Resverlogix Corp.
|
Sep 30, 2019 06:14AM
|
